Cargando…

肺鳞癌分子靶向治疗的研究现状

Lung cancer is one of the world's highest morbidity and mortality disease in malignant tumors currently.Squamous-cell lung cancer (SQCLC) is one of the most prevalent subtypes of lung cancer worldwide, after surgery, radiotherapy, chemotherapy and other comprehensive treatment, its 5-year survi...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000367/
https://www.ncbi.nlm.nih.gov/pubmed/25130969
http://dx.doi.org/10.3779/j.issn.1009-3419.2014.08.07
_version_ 1783331699662258176
collection PubMed
description Lung cancer is one of the world's highest morbidity and mortality disease in malignant tumors currently.Squamous-cell lung cancer (SQCLC) is one of the most prevalent subtypes of lung cancer worldwide, after surgery, radiotherapy, chemotherapy and other comprehensive treatment, its 5-year survival rate is still below 15%.The current molecular targeted therapy plays an important role in the treatment of SQCLC, an urgent need to be more in-depth study.SQCLC molecular targeted therapy mainly epidermal growth factor receptor (EGFR), phosphoin-3-kinase catalytic alpha polypeptide (PIK3CA), fibroblast growth factor receptor 1 (FGFR1), discoidin domain receptor 2 (DDR2), phosphatase and tensin homolog deleted on chromosome ten (PTEN), BRAF, MET, insulin-like growth factor 1 receptor (IGF-1R) and other as the target of the drug, some targeted drugs are being developed, and some targeted drugs have entered clinical trials.In recent years, with studies molecular targeted therapy in SQCLC, analysis of the development and trgeted therapy achieved substantial progress in improving the survival rate of SQCLC, and other research to improve the quality of life, make is possible to individualized targeted therapy of SQCLC.
format Online
Article
Text
id pubmed-6000367
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60003672018-07-06 肺鳞癌分子靶向治疗的研究现状 Zhongguo Fei Ai Za Zhi 综述 Lung cancer is one of the world's highest morbidity and mortality disease in malignant tumors currently.Squamous-cell lung cancer (SQCLC) is one of the most prevalent subtypes of lung cancer worldwide, after surgery, radiotherapy, chemotherapy and other comprehensive treatment, its 5-year survival rate is still below 15%.The current molecular targeted therapy plays an important role in the treatment of SQCLC, an urgent need to be more in-depth study.SQCLC molecular targeted therapy mainly epidermal growth factor receptor (EGFR), phosphoin-3-kinase catalytic alpha polypeptide (PIK3CA), fibroblast growth factor receptor 1 (FGFR1), discoidin domain receptor 2 (DDR2), phosphatase and tensin homolog deleted on chromosome ten (PTEN), BRAF, MET, insulin-like growth factor 1 receptor (IGF-1R) and other as the target of the drug, some targeted drugs are being developed, and some targeted drugs have entered clinical trials.In recent years, with studies molecular targeted therapy in SQCLC, analysis of the development and trgeted therapy achieved substantial progress in improving the survival rate of SQCLC, and other research to improve the quality of life, make is possible to individualized targeted therapy of SQCLC. 中国肺癌杂志编辑部 2014-08-20 /pmc/articles/PMC6000367/ /pubmed/25130969 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.08.07 Text en 版权所有©《中国肺癌杂志》编辑部2014 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 综述
肺鳞癌分子靶向治疗的研究现状
title 肺鳞癌分子靶向治疗的研究现状
title_full 肺鳞癌分子靶向治疗的研究现状
title_fullStr 肺鳞癌分子靶向治疗的研究现状
title_full_unstemmed 肺鳞癌分子靶向治疗的研究现状
title_short 肺鳞癌分子靶向治疗的研究现状
title_sort 肺鳞癌分子靶向治疗的研究现状
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000367/
https://www.ncbi.nlm.nih.gov/pubmed/25130969
http://dx.doi.org/10.3779/j.issn.1009-3419.2014.08.07
work_keys_str_mv AT fèilínáifēnzibǎxiàngzhìliáodeyánjiūxiànzhuàng
AT fèilínáifēnzibǎxiàngzhìliáodeyánjiūxiànzhuàng
AT fèilínáifēnzibǎxiàngzhìliáodeyánjiūxiànzhuàng